 Uniqure NV NASDAQ: QURE has reported results of a comprehensive investigation into the case of hepatocellular carcinoma HCC diagnosed in one patient in the HOPE-B pivotal trial of etranacogene dezaparvovec, its hemophilia B gene therapy candidate. What Happened: The trial was put on clinical last year in December, following the submission of a safety report in mid-December relating to a possibly related severe adverse event associated with a preliminary diagnosis of hepatocellular carcinoma in one patient. 